Entecavir, Adefovir — Competitive Intelligence Brief

Entecavir, Adefovir (Entecavir, Adefovir) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Nucleoside/nucleotide reverse transcriptase inhibitor. Area: Virology/Hepatology.

marketed Nucleoside/nucleotide reverse transcriptase inhibitor Hepatitis B virus polymerase (reverse transcriptase) Virology/Hepatology Small molecule

Target snapshot

Entecavir, Adefovir (Entecavir, Adefovir) — Nanfang Hospital, Southern Medical University. Entecavir and Adefovir are nucleoside/nucleotide reverse transcriptase inhibitors that block hepatitis B virus replication by inhibiting the viral polymerase enzyme.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Entecavir, Adefovir TARGET	Entecavir, Adefovir	Nanfang Hospital, Southern Medical University	marketed	Nucleoside/nucleotide reverse transcriptase inhibitor	Hepatitis B virus polymerase (reverse transcriptase)
DTG/3TC/ABC + ELV/COBI/FTC/TAF	DTG/3TC/ABC + ELV/COBI/FTC/TAF	Fundacion SEIMC-GESIDA	marketed	Antiretroviral combination therapy (integrase inhibitor + nucleoside/nucleotide reverse transcriptase inhibitors)	HIV integrase, HIV reverse transcriptase
Multiple Product PrEP Program	Multiple Product PrEP Program	University of Alabama at Birmingham	marketed	Antiretroviral combination therapy (nucleoside/nucleotide reverse transcriptase inhibitors)	HIV reverse transcriptase, HIV integrase
FTC-TDF PrEP	FTC-TDF PrEP	University of Washington	marketed	Nucleoside/nucleotide reverse transcriptase inhibitor combination	HIV reverse transcriptase
B/FTC/TAF	B/FTC/TAF	The University of Texas Health Science Center, Houston	marketed	Antiretroviral combination (integrase inhibitor + nucleoside/nucleotide reverse transcriptase inhibitors)	HIV integrase, HIV reverse transcriptase
tenofovir disproxil fumarate/emtricitabine	tenofovir disproxil fumarate/emtricitabine	Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections	marketed	Nucleoside/nucleotide reverse transcriptase inhibitor combination	HIV reverse transcriptase
Emtricitabine/tenofovir or abacavir/lamivudine	Emtricitabine/tenofovir or abacavir/lamivudine	Fundacion SEIMC-GESIDA	marketed	Nucleoside/nucleotide reverse transcriptase inhibitor (NRTI)	HIV reverse transcriptase

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Nucleoside/nucleotide reverse transcriptase inhibitor class)

1. Bristol-Myers Squibb · 1 drug in this class
2. Nanfang Hospital, Southern Medical University · 1 drug in this class
3. Third Affiliated Hospital, Sun Yat-Sen University · 1 drug in this class
4. University of Washington · 1 drug in this class